Actinium-225 targeted alpha particle therapy for prostate cancer
Theranostics · 2024 · 14 (7) · 2969-2992
DOI: 10.7150/thno.96403 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Theranostics, 2024. Verfasst von Anil P Bidkar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California San Francisco, CA-94107, USA. Hauptthemen laut MEDLINE: Actinium, Prostatic Neoplasms, Alpha Particles. Die Arbeit wurde bisher 97-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Biomedical Imaging, University of California San Francisco, CA-94107, USA.
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA-94107, USA.
- Department of Pharmaceutical Chemistry, University of California, San Francisco, CA-94107, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Bidkar, A. P., Zerefa, L., Yadav, S., VanBrocklin, H. F., & Flavell, R. R. (2024). Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics, 14(7), 2969-2992. https://doi.org/10.7150/thno.96403
Vancouver
Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 2024;14(7):2969-2992. doi:10.7150/thno.96403
BibTeX
@article{Bidkar2024,
author = {Bidkar, Anil P and Zerefa, Luann and Yadav, Surekha and VanBrocklin, Henry F and Flavell, Robert R},
title = {Actinium-225 targeted alpha particle therapy for prostate cancer},
journal = {Theranostics},
year = {2024},
volume = {14},
number = {7},
pages = {2969--2992},
doi = {10.7150/thno.96403}
}
EUVIMED